1-6 of 6 results for primarymember:"Jonathan Reynolds"
Librarians' tools
- Search time
- 0.219 seconds
- Solr query time
- 0.003 seconds
- Search query
- primarymember:"Jonathan Reynolds"
- We searched for
- primaryMember_ses:303201
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
Statement on the launch of the UK's modern industrial strategy.
Statement on the launch of the UK's modern industrial strategy.
Twentieth opposition day debate (part one). Motion that this House recognises that the automotive industry is the jewel in the crown of British manufacturing and believes it can have a bright future creating good jobs for people across the UK; regrets that after 13 years of Conservative neglect the UK risks losing this world-class industry, putting thousands of jobs under threat; condemns the Government for its lack of an industrial strategy and the negative impact this has had on investment in the UK's automotive sector; calls on the Government to urgently resolve the rules of origin changes which are due to take effect in 2024, working with partners across Europe to negotiate a deal that works for manufacturers; and further calls on the Government to adopt an active industrial strategy to build the battery factory capacity needed to secure the automotive sector for decades to come. Agreed to on question.
Twentieth opposition day debate (part one). Motion that this House recognises that the automotive industry is the jewel in the crown of British manufacturing and believes it can have a bright future creating good jobs for people across the UK; regrets that after 13 years of Conservative neglect the UK...
To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the potential impact of the Government not having a Minister for Science, Research and Innovation in post since July 2022.
To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment he has made of the potential impact of the Government not having a Minister for Science, Research and Innovation in post since July 2022.
My Rt. Hon. Friend the Secretary of State has been, and continues to be, the primary decision maker and minister responsible for science research and innovation policy. These policies remain a priority for this Government and BEIS have continued to make progress on science matters since July.
We are providing the fastest ever sustained uplift in R&D funding with government investment in R&D reaching £20 billion per annum by 2024-2025.
The appointment of Ministers is a matter for my Rt. Hon. Friend the Prime Minister.
To ask the Secretary of State for Health and Social Care, what steps he is taking to tackle delays in approval by NICE for the use of innovative cancer drugs on the NHS.
To ask the Secretary of State for Health and Social Care, what steps he is taking to tackle delays in approval by NICE for the use of innovative cancer drugs on the NHS.
New arrangements for the assessment and adoption of new cancer drugs were introduced in 2016 to help improve patient access to new cancer drugs, including through the Government established Cancer Drugs Fund.
The National Institute for Health and Care Excellence is now committed to publishing final guidance within 90 days of a new cancer drug receiving its licence and aims to publish its draft recommendation before a licence is granted. The forecasted mean time from a new cancer drug receiving its licence to published final guidance in 2020/21 is now 1.5 months which is a reduction of 13.5 months from 2012/13. The speed of appraisal output is affected by appeals, late referrals, additional committee meetings and companies negotiating revised timing of appraisals.
We Labour Members believe that encouraging investment is essential to making our economy more productive, and we recognise that that will be especially important post Brexit. Does the Treasury have a genuine indicator of how foreign direct investment has been affected by the referendum result, given that it was recently revealed that the Department for International Trade’s figures incorrectly include decisions taken before the vote for Brexit?
We Labour Members believe that encouraging investment is essential to making our economy more productive, and we recognise that that will be especially important post Brexit. Does the Treasury have a genuine indicator of how foreign direct investment has been affected by the referendum result, given that it was recently revealed that the Department for International Trade’s figures incorrectly include decisions taken before the vote for Brexit?
We are at an early stage, in terms of the impact on foreign direct investment. On the level of business investment since the referendum, the numbers have held up pretty strongly, although, as I say, it is early days and early data. The hon. Gentleman says he welcomes business investment in this country; he should listen to some of the things his party leadership is saying, which would do nothing but drive business out of the United Kingdom.
To ask the Secretary of State for Health, whether the consultation on the database created by the Access to Medical Treatments (Innovation) Act 2016 will involve (a) medical research charities, (b) the pharmaceutical sector and (c) the Medicines and Healthcare Products Regulatory Agency.
To ask the Secretary of State for Health, whether the consultation on the database created by the Access to Medical Treatments (Innovation) Act 2016 will involve (a) medical research charities, (b) the pharmaceutical sector and (c) the Medicines and Healthcare Products Regulatory Agency.
The Health and Social Care Information Centre will consult with stakeholders including charities, the relevant Royal Colleges, industry, the Medicines and Healthcare products Regulatory Agency and other relevant bodies in the creation of the Database described in the Act, when the power vested on the Secretary of State is enacted.